Gastrointestinal Drugs Global Market Report 2018

1
Gastrointestinal Drugs Global Market Report 2018
Including Antiulcerants Vitamin And Minerals
Antacids Antiemetics And Antinauseants
Antiobesity Antidiarrhoeals Covering Takeda
Pharmaceuticals, Allergan Plc, Novo Nordisk A/S,
AstraZeneca Plc, Johnson Johnson
Feb 2018
2
Reasons to Purchase

• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high
  quality data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Antiulcerants Vitamin And
  Minerals Antacids Antiemetics And
• Antinauseants Antiobesity Antidiarrhoeals
• Companies Mentioned Takeda Pharmaceuticals,
  Allergan Plc, Novo Nordisk A/S, AstraZeneca Plc,
  Johnson Johnson
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.
• Regions Asia-Pacific, Western Europe, Eastern
  Europe, North America, South America, Middle
  East And Africa

3
Gastrointestinal Drugs Market Characteristics
The gastrointestinal diseases drugs market
covers medicines used for the treatment of
ulcerative colitis, diverticular disease,
perianal infections, anal fissures, hemorrhoids,
constipation, and irritable bowel syndrome. The
key gastrointestinal diseases drug categories
include Anti-peptic agents (antacids,
antagonists, Proton Pump Inhibitors, Sucralfate,
and Misoprostol), antiemetics, adsorbents,
anticholinergics, opiates, intestinal flora
modifiers, emollient/surfactants, hyperosmotic,
saline, and simulant/irritant. The market
numbers within this briefing are restricted to
pharmaceutical (drug) treatments and do not
cover biologic treatments for these conditions
which are included in a separate briefing. This
market is further classified as Antacids
Antacids are medications that neutralize stomach
acid. They are used to treat acid reflux,
heartburn and indigestion. Alka
Seltzer, Vitamins Minerals Vitamins are
organic compounds essential for nutrition and
growth of the body. Minerals are inorganic
substances that Antiulcerants Antiulcerants
are used to treat ulcers in the stomach and upper
part of the small intestine. For example, Axid,
Carafate, Antiobesity Antiobesity medications
are pharmacological agents that reduce or
control weight. Orilstat, Phentermine/ Antiemetic
s And Antinauseants Antiemetics are used to
treat motion sickness and are effective
against Antidiarrhoeals Antidiarrhoeal
medications provide symptomatic relief for
diarrhea.
4
In this report market value is defined as the
revenues organizations earn by selling their
goods and services within the specified market,
based on the price at which they sell. Only
goods and services traded between entities are
included. The revenues for a specified geography
are consumption values that is, they are
revenues generated by organizations in the
specified geography within the specified
market, irrespective of where they are produced.
5
Gastrointestinal Drugs Market Historic Growth
The global gastrointestinal drugs market grew
from X billion in 2013 to X billion in 2017 at
a compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global gastrointestinal drugs
market during 2013 2017.
Drivers of the Market Restraints on the Market
6
Gastrointestinal Drugs Market Forecast Growth
The global gastrointestinal drugs market is
expected to grow from XX billion in 2017 to 65
billion in 2021 at a compound annual growth rate
(CAGR) of XX. This can be attributed to the
expected increase in prevalence of obesity and
digestive diseases globally. The chart and
table below shows the year-on-year growth of the
global gastrointestinal drugs market during 2017
- 2021.
Drivers of the Market Restraints on the Market
7
Gastrointestinal Drugs Market Segmentation
The chart and table below shows the split of the
gastrointestinal drugs market in 2017.
The total market value for gastrointestinal drugs
was X billion in 2017. The markets that are
covered include Antiulcerants Vitamin And
Minerals Antacids Antiemetics And
Antinauseants Antiobesity Antidiarrhoeals. Anti
ulcerants was the X largest segment in the
gastrointestinal drugs market with X share of
the market. The market value for the
antiulcerants was X billion in 2017. Vitamin
And Minerals made up around X share of the
market. The market value for the vitamin and
minerals was X billion in 2017.
8
Gastrointestinal Drugs Market Regional And
Country Analysis
The Asia Pacific was the largest region in the
gastrointestinal drugs market in 2017,
gastrointestinal drugs for X billion or X
market share. North America was the x largest
region gastrointestinal drugs for X billion or
X market share. Western Europe was the x
largest region gastrointestinal drugs for X
billion or X market share.
9
Gastrointestinal Drugs Market Competitive
Landscape
The leading competitors in the global
gastrointestinal drugs market are Takeda
Pharmaceuticals, Allergan Plc, Novo Nordisk A/S,
AstraZeneca Plc, Johnson Johnson. The chart
and table below displays the percentage market
share of the top players in the gastrointestinal
drugs market industry.
Takeda Pharmaceuticals generated revenues of XX
billion for the financial year 2015, an XX
increase from the previous year. Allergan Plc.
generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Novo Nordisk A/S generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. AstraZeneca Plc. generated revenues of XX
billion for the financial year 2016, an XX
decrease from the previous year.
10
Johnson Johnson generated revenues of XX
billion for the financial year 2016, an XX
increase from the previous year. Bayer AG
generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Otsuka Pharmaceutical Co., Ltd.
generated revenues of XX billion for the
financial year 2016, an XX decrease from the
previous year. Company Profile Takeda
Pharmaceuticals Overview Takeda Pharmaceuticals
was the largest competitor in the
gastrointestinal diseases drugs market in 2017
with XX share of the market. Takeda is a
pharmaceutical company which develops,
manufactures and sells medications in various
therapeutic areas including oncology,
gastroenterology, central nervous system,
vaccines and others. The company is
headquartered in Osaka, Japan. Products and
Services Takeda operates through following
division The Ethical Drugs division is
involved in manufacture and The Consumer
Healthcare division manufactures and sells The
Others division manufactures and
sells Strategy Takeda aims to harness new
technologies and targeted treatments to develop
innovative and new medicines for the treatment of
gastrointestinal diseases. In 2014, the
company launched ENTYVIO (vedolizumab), a
gut-selective biologic for the treatment of
11
Financial Performance Takedas Ethical Drugs
division, involved in gastrointestinal diseases
drugs manufacturing, generated revenues of JPY
557.5 billion (5.1 billion) in 2015, an
increase of XX over previous year. The company
had a market Allergan Plc Overview Products and
Services Strategy Financial Performance Novo
Nordisk A/S Overview Products and Services
Strategy Financial Performance AstraZeneca
Plc Overview Products and Services
Strategy Financial Performance Johnson
Johnson Overview Products and Services
Strategy Financial Performance